William Blair analyst Sami Corwin has maintained their bullish stance on ACLX stock, giving a Buy rating today.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Sami Corwin has given his Buy rating due to a combination of factors that highlight Arcellx Inc’s promising future. The company’s anito-cel treatment for relapsed/refractory multiple myeloma has shown impressive efficacy and safety results, with no significant neurotoxicity events reported in patients treated over a year ago. This strong safety profile, coupled with high efficacy and minimal residual disease negativity rates, positions anito-cel as a leading option in the competitive BCMA CAR-T and bispecifics market.
Additionally, the anticipated acceptance of the BLA submission is expected to act as a catalyst for the company, potentially leading to a priority review. Arcellx’s strategic partnership with Kite, which provides a robust commercial infrastructure and efficient manufacturing processes, is likely to support a successful market launch and sustained commercial performance. These elements, along with the potential for earlier-line adoption and outpatient use, underpin Corwin’s optimistic outlook and Buy rating for Arcellx Inc.
Corwin covers the Healthcare sector, focusing on stocks such as Neurogene, uniQure, and Solid Biosciences. According to TipRanks, Corwin has an average return of 16.7% and a 57.20% success rate on recommended stocks.
In another report released today, Needham also maintained a Buy rating on the stock with a $105.00 price target.